Lipocine vs Nutriband
Lipocine and Nutriband are similar in size: $2.0m and $2.0m of revenue in their latest fiscal years. Nutriband grew faster (-4.8% against -82.3%). Nutriband kept more of each dollar of sales as profit: a net margin of -404.1% against -487.1%. Lipocine carries less debt relative to equity (0.0% against 0.5%).
| Latest fiscal year | LipocineLPCN, 2025 | NutribandNTRB, 2026 |
|---|---|---|
| Revenue | $2.0m | $2.0m |
| Revenue growth | -82.3% | -4.8% |
| Net income | −$9.6m | −$8.2m |
| Operating margin | -524.7% | -408.4% |
| Net margin | -487.1% | -404.1% |
| Return on equity | -54.3% | -125.6% |
| Free cash flow | −$9.8m | −$5.1m |
| Cash | $5.2m | $4.6m |
| Total debt | $0 | $35,861 |
| Debt to equity | 0.0% | 0.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | 500 |
| Market value | $12.0m | $76.8m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 7 buys, 0 sales | 0 buys, 0 sales |